CPA1 and neoplasm: It is noteworthy that the dual CD47/PD‐L1 blockade treatment induced by free antibodies of CPA demonstrated a dose‐dependent synergistic enhanced effect in tumor growth inhibition due to the deficient tumor accumulation of systemic administration of free antibodies induced by the on‐target off‐tumor immunotoxicity.